Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.37 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5402698 | 0.88 | EPHX2 (0.48) | EPHX2LMNAANPEPERAP2ERAP1 | |
| SCHEMBL7526215 | 0.83 | EPHX2 (0.40) | EPHX2LMNAKDM4ESMN1; SMN2 | |
| SCHEMBL7533696 | 0.81 | SMN1; SMN2 (0.47) | LMNATDP1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL5401685 | 0.80 | PLA2G4B (0.40) | EPHX2TDP1ALDH1A1MAPT | |
| SCHEMBL5407625 | 0.80 | MTNR1A (0.37) | EPHX2LMNAALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL5421203 | 0.79 | MTNR1A (0.36) | EPHX2ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL5403079 | 0.79 | SMN1; SMN2 (0.45) | EPHX2LMNAALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL5406745 | 0.77 | EPHX2 (0.41) | CYP19A1EPHX2LMNALTA4HANPEP | |
| SCHEMBL5413344 | 0.76 | PLA2G4B (0.47) | LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL7528911 | 0.76 | TSHR (0.48) | ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7247645-B2 | Dihydropyridine derivatives | AJINOMOTO CO., INC. (JP) | 2007-07-24 | — | — | US | disclosed |
| US-20020147222-A1 | Dihydropyridine derivatives | AJINOMOTO CO. INC (JP) | 2002-10-10 | — | — | US | disclosed |
| EP-1191021-A1 | DIHYDROPYRIDINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2002-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147222-A1 | Dihydropyridine derivatives | CACNA1B, CACNA1D, CACNA1C | CYP19A1 3954/4885EPHX2 3229/4885LMNA 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.